24
Participants
Start Date
May 31, 2010
Primary Completion Date
June 30, 2010
Study Completion Date
August 31, 2010
CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet
From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
CKD-501 placebo tablet, Glimepiride 4 mg tablet
From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
The Korea University Anam Hospital, Seoul
Lead Sponsor
Chong Kun Dang Pharmaceutical
INDUSTRY